SCHEMBL6889065

SCHEMBL6889065

Nc1ccc(N2CCN3CCC2CC3)cc1C(=O)NC1CC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.41
SMYD3 Q9H7B4 3/20 0.41
BMPR1B O00238 3/20 0.40
BMPR1A P36894 3/20 0.40
TGFBR1 P36897 3/20 0.40
ACVRL1 P37023 3/20 0.40
ACVR1 Q04771 3/20 0.40
CHRNA7 P36544 3/20 0.39
MCHR1 Q99705 1/20 0.39
CHRNA1 P02708 3/20 0.38
CHRNB2 P17787 3/20 0.38
CHRNB4 P30926 3/20 0.38
CHRNA3 P32297 3/20 0.38
CHRNA4 P43681 3/20 0.38
HTR3A P46098 2/20 0.38
IP6K1 Q92551 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6887891 0.95 BMPR1B (0.43) KCNH2SMYD3BMPR1BBMPR1ATGFBR1
SCHEMBL6888796 0.86 KCNH2 (0.42) KCNH2CHRNA7CHRNA1CHRNB2CHRNB4
SCHEMBL1670851 0.84 KCNH2 (0.38) KCNH2CHRNA7CHRNA1CHRNB2CHRNB4
SCHEMBL6887709 0.84 ALDH1A1 (0.57) KCNH2
SCHEMBL11905011 0.83 KCNH2 (0.40) KCNH2CHRNA7CHRNA1CHRNB2CHRNB4
SCHEMBL6887526 0.83 KCNH2 (0.40) KCNH2CHRNA7CHRNA1CHRNB2CHRNB4
SCHEMBL1670054 0.83 KCNH2 (0.45) KCNH2CHRNA7CHRNA1CHRNB2CHRNB4
SCHEMBL6889001 0.83 KCNH2 (0.38) KCNH2CHRNA7CHRNA1CHRNB2CHRNB4
SCHEMBL1667724 0.82 USP5 (0.41) KCNH2CHRNA7CHRNA1CHRNB2CHRNB4
SCHEMBL6888392 0.82 KCNH2 (0.39) KCNH2CHRNA7CHRNA1CHRNB2CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488520-B1 CONDENSED AZINE-DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR MERCK SHARP & DOHME (NL) 2015-09-02 EP disclosed
EP-2488520-B1 CONDENSED AZINE-DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR MERCK SHARP & DOHME (NL) 2015-09-02 EP disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
WO-2011045258-A1 CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR N.V. ORGANON (NL) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208796-A1 HETEROCYCLIC DERIVATIVES CHRNA5, CHRM5, CHRNA7 KCNH2 728/4885SMYD3 1091/4885BMPR1B 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.